EP
Eversept Partners’s Teva Pharmaceuticals TEVA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.6M | Sell |
1,052,881
-357,884
| -25% | -$6M | 1.62% | 20 |
|
|
2025
Q1 | $21.7M | Sell |
1,410,765
-831,360
| -37% | -$12.8M | 2.2% | 12 |
|
|
2024
Q4 | $49.4M | Sell |
2,242,125
-992,513
| -31% | -$21.9M | 4.39% | 6 |
|
|
2024
Q3 | $58.3M | Sell |
3,234,638
-1,485,822
| -31% | -$26.8M | 3.99% | 8 |
|
|
2024
Q2 | $76.7M | Sell |
4,720,460
-1,304,709
| -22% | -$21.2M | 5.25% | 4 |
|
|
2024
Q1 | $85M | Sell |
6,025,169
-129,185
| -2% | -$1.82M | 5.67% | 4 |
|
|
2023
Q4 | $64.3M | Sell |
6,154,354
-797,731
| -11% | -$8.33M | 5.64% | 5 |
|
|
2023
Q3 | $70.9M | Sell |
6,952,085
-715,959
| -9% | -$7.3M | 6% | 3 |
|
|
2023
Q2 | $57.7M | Buy |
7,668,044
+1,473,472
| +24% | +$11.1M | 4.83% | 3 |
|
|
2023
Q1 | $54.8M | Buy |
6,194,572
+1,481,975
| +31% | +$13.1M | 3.82% | 4 |
|
|
2022
Q4 | $43M | Buy |
4,712,597
+649,662
| +16% | +$5.92M | 3.76% | 7 |
|
|
2022
Q3 | $32.8M | Sell |
4,062,935
-447,767
| -10% | -$3.61M | 2.84% | 8 |
|
|
2022
Q2 | $33.9M | Buy |
4,510,702
+367,100
| +9% | +$2.76M | 2.41% | 9 |
|
|
2022
Q1 | $38.9M | Buy |
4,143,602
+1,842,104
| +80% | +$17.3M | 2.99% | 9 |
|
|
2021
Q4 | $18.4M | Sell |
2,301,498
-1,253,306
| -35% | -$10M | 1.18% | 19 |
|
|
2021
Q3 | $34.6M | Sell |
3,554,804
-249,601
| -7% | -$2.43M | 2.39% | 13 |
|
|
2021
Q2 | $37.7M | Sell |
3,804,405
-550,351
| -13% | -$5.45M | 2.51% | 9 |
|
|
2021
Q1 | $50.3M | Buy |
4,354,756
+1,606,506
| +58% | +$18.5M | 3.78% | 6 |
|
|
2020
Q4 | $26.5M | Buy |
2,748,250
+353,895
| +15% | +$3.42M | 3.11% | 13 |
|
|
2020
Q3 | $21.6M | Buy |
+2,394,355
| New | +$21.6M | 4.79% | 6 |
|